Generative AI-Designed TEAD Inhibitor Shows 40% Response Rate in Heavily Pretreated Mesothelioma
A Phase 1 trial presented at ESMO 2026 reports a 40% objective response rate at 130 mg for ISM6331, a ...
A Phase 1 trial presented at ESMO 2026 reports a 40% objective response rate at 130 mg for ISM6331, a ...
Insilico Medicine plans to present first human Phase 1 data for the AI-designed pan-TEAD inhibitor ISM6331 in mesothelioma and other ...
Insilico Medicine will present the first clinical data for its AI-designed pan-TEAD inhibitor ISM6331 in a Rapid Oral session at ...
© 2026 Scienmag - Science Magazine
© 2026 Scienmag - Science Magazine